MetaVia Inc. announced that its novel obesity drug candidate DA-1726, a dual GLP-1 and glucagon receptor agonist, will be featured in a late-breaking poster at the EASL Congress 2026 in Barcelona. DA-1726 aims to reduce weight by decreasing appetite and increasing energy use, showing superior results in pre-clinical studies compared to existing treatments. The drug is currently in a Phase 1 trial to optimize dosing, with results expected in Q4 2026. This highlights MetaVia's progress in developing innovative treatments for cardiometabolic diseases.
The global automotive microcontrollers market is projected to grow from USD 15.49 billion in 2025 to USD 34.31 billion by 2035, at a CAGR of 8.28%. Growth is fueled by increasing adoption of advanced driver-assistance systems (ADAS), vehicle electrif...
Sodexo has secured a major global contract to provide catering services across more than 130 Meta sites in over 30 countries. This large-scale partnership includes diverse locations such as headquarters, campuses, data centers, and conference centers...
NVIDIA and Noetra Corp. are partnering to build Japan's first national AI infrastructure, the NVIDIA Vera Rubin AI factory, featuring 13,750 Vera CPUs and 27,500 Rubin GPUs. Supported by Japan's Ministry of Economy, Trade and Industry, this 140-megaw...
Flight searches from the UK to destinations along the path of the August 12, 2026 solar eclipse have surged, with increases up to 201% for Spain's Cantabrian Coast and over 100% for Reykjavik, Iceland. This eclipse is notable as the first visible tot...
Solana (SOL) has gained about 30% from its June low, trading around $78 and surpassing its 50-day EMA. The token's upward momentum is supported by increased speculative trading and a new SuperTrend buy signal, the first since October 2025. However, i...
